Moderna ($MRNA) Crashes 26% on Leaked Phase 3 Cancer Vaccine Data
Leaked Phase 3 data for Moderna's melanoma vaccine shows 42% risk reduction, below the 49% from Phase 2b, triggering a collapse that wiped ~$12B in market cap and sent institutions fleeing.
What we know
An account on X reported MRNA down 26% after leaked Phase 3 (INTERPATH-001) data showed Merck's mRNA cancer vaccine plus Keytruda reduced melanoma recurrence or death risk by 42%, versus 49% in the prior Phase 2b trial. Another account on X confirmed $12B was wiped out amid institutional selling. Merck officially released results showing the combo also achieved a 58% reduction on a secondary measure with a consistent safety profile. Another account on X warned traders not to be distracted by the MRNA saga and to focus on identifying the broader market bottom.
How the story developed
Leaked Phase 3 data for Moderna's melanoma vaccine shows 42% risk reduction, below the 49% from Phase 2b, triggering a collapse that wiped ~$12B in market cap and sent institutions fleeing.
Moderna shares fell ~24-25% after Phase 3 melanoma results from its cancer vaccine trial appeared to leak on a medical news site before being quickly removed.
A CT trader called 'Togi' went full port into short-term OTM Moderna puts; within the hour MRNA dumped 10%+ and was halted. The trade became a viral moment across multiple communities, and MRNA remained tradeable on crypto exchanges despite the TradFi halt.
By the Global Eye 24 desk, with AI assistance. Updated as the story develops. Spot an error? Write to corrections@globaleye24.com.